TNFRSF4 and neoplasm: Clinical studies have shown that combining OX40 agonists with chemotherapy enhances antitumor responses, chemotherapy increases antigen availability and presentation, and OX40 signaling heightens T cell recognition of tumor antigens and reverses immune suppression within the tumor microenvironment (120).